Dizal and Daiichi have set the bar, but a lack of other interest in ITK inhibition could ring alarm bells.

The company sticks with EZH2, despite others adding EZH1 inhibition.

Daiichi aims to expand valemetostat into a new use, but Haihe Biopharma isn't far behind.

The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.